by The global Dupuytrens disease market consists of products such as collagenase clostridium histolyticum which provides effective treatment for soft tissue defects and joints contractures caused by Dupuytren’s disease. Dupuytrens disease, a thickening and contracting of tissues under the skin in the palm of the hand, causes fingers to curl inward towards the palm and limits finger movement. Collagenase clostridium histolyticum treatment helps in breaking down collagen strands that cause contracture in Dupuytren’s disease, thereby enabling better finger movement.
The Global Dupuytrens Disease Market is estimated to be valued at Us$ 4.3 Bn in 2024 and is expected to exhibit a CAGR Of 4.6% over the forecast period 2024 To 2030.
Key Takeaways
Key players operating in the Global Dupuytrens Disease Market Demand are Endo International Plc, Bristol-Meyers Squibb Company, Spear Pharmaceuticals, GSK Plc., AstraZeneca, Hikma Pharmaceuticals Plc, LEO Pharma A/S, Fresenius Kabi AG, Bayer AG, Novartis AG, Pfizer Inc., Nantong Jinghua Pharmaceutical Co., Ltd., and Actiza Pharmaceutical Pvt. Ltd., 180 Life Sciences Corp. Key players are focused on developing advanced treatment options and expanding their product offerings to tap increasing demands.
The global Dupuytrens disease market is witnessing high growth due to increasing prevalence of Dupuytren’s contracture and lack of permanent cure. As per estimates, around 3-6% of the general population suffers from Dupuytren’s disease worldwide. Rising awareness about available treatment options and growing geriatric population are also contributing to market growth.
Major players are focused on penetrating developing markets through strategic collaborations, partnerships and acquisitions to leverage high growth opportunities. For instance, in 2023, Spear Pharmaceuticals expanded its global footprint by receiving approval to market Xiapex in South Korea for treatment of Dupuytren’s contracture.
Market key trends
One of the key trends witnessed in the global Dupuytrens disease market is rising number of clinical trials focused on developing advanced medications with improved efficacy. For example, in 2023, 180 Life Sciences announced positive topline results from Phase 2b clinical trial evaluating 180-001, a non-surgical collagenase treatment for mild and moderate Dupuytren’s contracture. The study demonstrated statistically significant reduction in contracture with 180-001 treatment. Several other players are also exploring gene therapy and stem cell-based novel treatment approaches to offer cure for the chronic disease. Advancing research holds potential to drive high adoption of innovative therapies over the forecast period.
Porter’s Analysis
Threat of new entrants: High capital requirements in the pharmaceutical industry makes it difficult for new players to enter the market.
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of treatment options.
Bargaining power of suppliers: Established suppliers have bargaining power due to specialized expertise required.
Threat of new substitutes: Limited threat as Dupuytren’s disease has no complete cure and management focuses on relieving symptoms.
Competitive rivalry: Intense competition due to large number of players and focus on novel therapies.
Geographical Regions
North America accounts for the largest share of the global Dupuytren’s disease market in terms of value owing to rising prevalence and rapid adoption of advanced treatment options. The region is projected to continue dominating the market during the forecast period.
Asia Pacific is poised to witness the fastest growth over 2024-2030. This is attributed to increasing awareness, improving healthcare infrastructure and rising healthcare spending in densely populated countries such as China and India. Supportive regulatory framework and focus on providing universal healthcare will aid Asia Pacific in gaining market share.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
